| 3.92 0.11 (2.89%) | 11-19 15:13 | |||||||||||||
|
|
| Short term | |
|||
| Mid term | ||||
| Targets | 6-month : | 5.19 | 1-year : | 6.07 |
| Resists | First : | 4.44 | Second : | 5.19 |
| Pivot price | 3.86 |
|||
| Supports | First : | 3.55 | Second : | 3 |
| MAs | MA(5) : | 3.69 |
MA(20) : | 3.92 |
| MA(100) : | 4.94 |
MA(250) : | 5.66 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 69.9 |
D(3) : | 46.1 |
| RSI | RSI(14): 52.7 |
|||
| 52-week | High : | 7.59 | Low : | 3 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IMA ] has closed below upper band by 28.6%. Bollinger Bands are 66.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.99 - 4.01 | 4.01 - 4.02 |
| Low: | 3.73 - 3.75 | 3.75 - 3.77 |
| Close: | 3.77 - 3.81 | 3.81 - 3.84 |
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
Thu, 12 Nov 2026
Imagenebio, Inc (IMA) Stock Price, News, Earnings & Company Profile - RTTNews
Thu, 12 Nov 2026
Here's Why We're Watching ImageneBio's (NASDAQ:IMA) Cash Burn Situation - Simply Wall St
Tue, 10 Nov 2026
ImageneBio, Inc. (IMA) Misses Q3 EPS by 11c - StreetInsider
Mon, 09 Nov 2026
ImageneBio Reports $15.6 Million Third-Quarter Net Loss - Moomoo
Mon, 09 Nov 2026
ImageneBio Reports Q3 2026 Results, $15.6 Million Net Loss - TradingView
Wed, 28 Oct 2026
ImageneBio (IMA) Jumps +3.58% — Is Institutional Money Flowing In? 2026-10-28 - Breakout Confirmation - https://www.siam.in/
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 11 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 16.1 (%) |
| Held by Institutions | 54.4 (%) |
| Shares Short | 61 (K) |
| Shares Short P.Month | 35 (K) |
| EPS | -4.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 12.6 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -43.1 % |
| Return on Equity (ttm) | -82.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -5.14 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -53 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -1.01 |
| PEG Ratio | 0 |
| Price to Book value | 0.32 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.89 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |